| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$36,313 ) |
| | 2023 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 001 | 1 | NIH | 3/17/2023 | -$10,236 |
| | 2023 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 000 | 1 | NIH | 3/17/2023 | -$26,076 |
|
| Issue Date FY: 2022 ( Subtotal = -$26 ) |
| | 2022 | 2019 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R44CA233143 | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | 000 | 2 | NIH | 6/29/2022 | -$26 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R44CA233143 | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | 000 | 2 | NIH | 8/12/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,091,666 ) |
| | 2019 | 2019 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R44CA233143 | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | 001 | 2 | NIH | 6/5/2019 | $1,091,666 |
| | 2019 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 000 | 1 | NIH | 1/2/2019 | $0 |
| | 2019 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 000 | 1 | NIH | 1/2/2019 | $0 |
| | 2019 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R44CA233143 | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | 000 | 1 | NIH | 5/17/2019 | $0 |
| | 2019 | 2017 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R43GM125462 | Effective engineering of the mitochondrial genome | 000 | 1 | NIH | 4/8/2019 | $0 |
| | 2019 | 2017 | B-MOGEN BIOTECHNOLOGIES INC | 1621 E HENNEPIN AVE SUITE B-15 | MINNEAPOLIS | MN | 55414-2489 | HENNEPIN | USA | R43HL135984 | Stable Gene Transfer by RNA Delivery | 000 | 1 | NIH | 4/16/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $443,444 ) |
| | 2018 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 614 MCKINLEY PL NE | MINNEAPOLIS | MN | 55413-2610 | HENNEPIN | USA | R44CA233143 | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | 000 | 1 | NIH | 8/6/2018 | $218,588 |
| | 2018 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 614 MCKINLEY PL NE | MINNEAPOLIS | MN | 55413-2610 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 000 | 1 | NIH | 8/8/2018 | $63,386 |
| | 2018 | 2018 | B-MOGEN BIOTECHNOLOGIES INC | 614 MCKINLEY PL NE | MINNEAPOLIS | MN | 55413-2610 | HENNEPIN | USA | R41OD026567 | Development of mitochondrial disease mouse models | 000 | 1 | NIH | 8/8/2018 | $161,470 |
|
| Issue Date FY: 2017 ( Subtotal = $449,198 ) |
| | 2017 | 2017 | B-MOGEN BIOTECHNOLOGIES INC | 614 MCKINLEY PL NE | MINNEAPOLIS | MN | 55413-2610 | HENNEPIN | USA | R43HL135984 | Stable Gene Transfer by RNA Delivery | 000 | 1 | NIH | 3/20/2017 | $224,634 |
| | 2017 | 2017 | B-MOGEN BIOTECHNOLOGIES INC | 614 MCKINLEY PL NE | MINNEAPOLIS | MN | 55413-2610 | HENNEPIN | USA | R43GM125462 | Effective engineering of the mitochondrial genome | 000 | 1 | NIH | 8/1/2017 | $224,564 |
|
|
